Cancer Center News

Study identified a drug for potential use in future precision medicine clinical trials

Children’s Hospital of Philadelphia (CHOP) announced that five of its physicians and researchers were among the ninety-eight new members selected to join the American Pediatric Society (APS), one of North America's first and most prestigious academic pediatric organizations.

Yael Mossé, MD, received the William Osler Patient Oriented Research Award, which was established in 1996 to honor Osler, a “Father of Clinical Medicine” who, in the 1800s, revolutionized clinical teaching and patient-oriented research at the Perelman School of Medicine at the University of Pennsylvania.

Made possible with a $4 million grant from the Brazilian Ministry of Health, CHOP cell therapy specialists will offer their expertise and resources to oversee this initiative.

Researchers at Children’s Hospital of Philadelphia (CHOP) have elucidated the significant role that alternative splicing – a process whereby a single gene produces multiple proteins by rearranging its messenger RNA segments in different combinations – plays in resistance to chemotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The study published today in the journal Cancer Research.

This award will help research, validate and implement a new model for sharing and integrating data at a national level.

Evan Weber will use this “high risk, high reward” grant to fund research into improving CAR-T therapies.

Researchers at Children’s Hospital of Philadelphia (CHOP) revealed for the first time that children, adolescents and young adults may experience very rare neurological issues of paraparesis and quadriparesis following chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy used to treat B-cell Acute Lymphoblastic Leukemia (B-ALL). Additionally, these complications occurred without the type of inflammation typically seen in adults. The findings were published today in the journal Blood.

CHOP researchers are aiming to treat a wider range of cancers by reaching previously “unreachable” drug targets.

Researchers in the Children’s Oncology Group (COG) at Children’s Hospital of Philadelphia (CHOP) are highlighting key factors influencing survival rates after the first relapse of acute lymphoblastic leukemia (ALL) in children. The study, which is the largest of its kind to evaluate leukemia relapse in children, was published recently in the journal Leukemia.